BRAIN Biotech AG (XTER:BNN) EBIT : €-6.17 Mil (TTM As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is BRAIN Biotech AG EBIT?

BRAIN Biotech AG's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2024 was €-1.38 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2024 was €-6.17 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. BRAIN Biotech AG's annualized ROC % for the quarter that ended in Mar. 2024 was -8.98%. BRAIN Biotech AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -26.77%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. BRAIN Biotech AG's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2024 was -11.33%.

BRAIN Biotech AG EBIT Historical Data

The historical data trend for BRAIN Biotech AG's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BRAIN Biotech AG EBIT Chart

BRAIN Biotech AG Annual Data

Trend

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

EBIT

Get a 7-Day Free Trial

-10.60

-9.27

-3.76

-5.64

-6.63

BRAIN Biotech AG Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
EBIT	Get a 7-Day Free Trial															-1.79	-1.84	-0.74	-2.21	-1.38

Competitive Comparison of BRAIN Biotech AG's EBIT

For the Specialty Chemicals subindustry, BRAIN Biotech AG's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BRAIN Biotech AG's EV-to-EBIT Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, BRAIN Biotech AG's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where BRAIN Biotech AG's EV-to-EBIT falls into.

BRAIN Biotech AG EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-6.17 Mil.

BRAIN Biotech AG (XTER:BNN) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

BRAIN Biotech AG's annualized ROC % for the quarter that ended in Mar. 2024 is calculated as:

	ROC % (Q: Mar. 2024 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Dec. 2023 )	+	Invested Capital (Q: Mar. 2024 ))	/ count )
=	-5.204 * ( 1 - -7.46% )	/	( (66.471	+	58.086)	/ 2 )
=	-5.5922184	/	62.2785
=	-8.98 %

where

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	66.471	-	0	-	( 0	-	max(0, 13.428	-	22.074	+	0	))
=	66.471

	Invested Capital		(Q: Mar. 2024 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	73.249	-	4.811	-	( 10.352	-	max(0, 14.576	-	29.303	+	10.352	))
=	58.086

Note: The Operating Income data used here is four times the quarterly (Mar. 2024) data.

2. Joel Greenblatt's definition of Return on Capital:

BRAIN Biotech AG's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2024 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Mar. 2024 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Dec. 2023		Q: Mar. 2024
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	-5.516	/	( ( (0 + max(8.646, 0))	+	(28.185 + max(4.375, 0)) )	/	2 )
=	-5.516	/	( ( 8.646	+	32.56 )	/	2 )
=	-5.516	/	20.603
=	-26.77 %

where Working Capital is:

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(0	+	0	+	22.074)	-	(0	+	0	+	13.428)
=	8.646

	Working Capital		(Q: Mar. 2024 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(8.71	+	8.886	+	1.355)	-	(4.811	+	0	+	9.765)
=	4.375

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2024) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

BRAIN Biotech AG's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Mar. 2024 )
	=	-6.167	/	54.442
	=	-11.33 %

BRAIN Biotech AG EBIT Related Terms

Thank you for viewing the detailed overview of BRAIN Biotech AG's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

BRAIN Biotech AG (XTER:BNN) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » BRAIN Biotech AG (XTER:BNN) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

BNN:Germany BNN:Germany BNN:Germany

Address

Darmstadter Strasse 34-36, Zwingenberg, BW, DEU, 64673

Website

https://www.brain-biotech.com

BRAIN Biotech AG is a technology company in the field of industrial biotechnology. It serves the chemical and consumer goods industries. The company develops novel biological ingredients such as enzymes, biocatalysts, and bioactive natural compounds. The company's segments include, BioProducts, BioScience and BioIncubator. Majority of the revenue is generated from its BioProducts segment which comprises of the product business with enzymes and other proteins for specific segments of the food industry. Geographically, the company generates majority of the revenue from United States of America and also has presence in other markets such as, Germany, France, United Kingdom and Netherlands.

Executives

Dr. Michael Majerus	Supervisory Board
Dr. Georg Kellinghusen	Supervisory Board
Michael Schneiders	Board of Directors
Adriaan Moelker	Board of Directors
Lukas Linnig	Board of Directors

BRAIN Biotech AG (XTER:BNN) Headlines

No Headlines